Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 30:13:112.
doi: 10.4103/abr.abr_134_23. eCollection 2024.

Diversity in the Clinical Course and Outcome of COVID-19 in Patients with Different Inborn Errors of Immunity can be Associated with the Type of Error

Negin Salemi  1 , Behrokh Shojaie  1 , Paria Bolourinejad  2 , Roya Sherkat  1 , Aryana Zamanifar  1 , Farhoodeh Ghaedrahmati  3 , Mahdieh Azizi  3 , Hamid Aria  3   4
Affiliations

Diversity in the Clinical Course and Outcome of COVID-19 in Patients with Different Inborn Errors of Immunity can be Associated with the Type of Error

Negin Salemi et al. Adv Biomed Res. .

Abstract

Background: The relationship between inborn errors of immunity (IEIs) and COVID-19 severity and incidence rates remains unclear due to limited and diverse data. This study aimed to address this gap by identifying specific IEIs associated with an increased risk of severe COVID-19 or a predisposition to severe disease before vaccination.

Materials and methods: Data were collected from the medical records of 15 patients with various IEIs, supplemented by interviews with individuals from an IEIs registry who had experienced COVID-19 before vaccination.

Results: Among the participants, only three patients (20%) experienced severe-prolonged COVID-19. Notably, this severity was predominantly observed in two male patients with Bruton's disease (BD) and one female patient with autosomal recessive hypogammaglobinemia. Moderate and severe COVID-19 cases were equally distributed (13.33%). In the female subgroup, one patient with common variable immunodeficiency and another with combined immunodeficiency experienced moderate and severe COVID-19, respectively. Conversely, both male patients with moderate and severe COVID-19 had BD.

Conclusion: Despite the limited number of severe cases, the absence of cytokine storm manifestation suggests potential protective mechanisms, possibly due to intravenous immunoglobulin therapy and inherent deficiencies within cytokine-producing cells (B and T cells). While IEIs may not be significant risk factors for COVID-19, they offer promising avenues for further research into therapeutic strategies targeting specific immune system components to mitigate severe COVID-19.

Keywords: Agammaglobulinemia; Covid-19; SARS-CoV-2; primary immunodeficiency disease.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
The distribution of the relative frequency of four levels of COVID-19 severities, namely mild, moderate, severe, and severe-prolonged, in patients with IEIs
Figure 2
Figure 2
The relative frequency of different IEIs in the male and female groups
Figure 3
Figure 3
The absolute frequency of patients with different IEIs in two groups of males and females who experienced different levels of COVID-19, namely mild, moderate, severe, and severe-prolonged
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Sood S, Aggarwal V, Aggarwal D, Upadhyay SK, Sak K, Tuli HS, et al. COVID-19 pandemic: From molecular biology, pathogenesis, detection, and treatment to global societal impact. Curr Pharmacol Rep. 2020;6:212–27. - PMC - PubMed
    1. Sharma HN, Latimore COD, Matthews QL. Biology and pathogenesis of SARS-CoV-2: Understandings for therapeutic developments against COVID-19. Pathogens. 2021;10:1218. - PMC - PubMed
    1. Andreakos E, Abel L, Vinh DC, Kaja E, Drolet BA, Zhang Q, et al. A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infection. Nat Immunol. 2022;23:159–64. - PMC - PubMed
    1. Ochani R, Asad A, Yasmin F, Shaikh S, Khalid H, Batra S, et al. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Infez Med. 2021;29:20–36. - PubMed
    1. Singh SP, Pritam M, Pandey B, Yadav TP. Microstructure, pathophysiology, and potential therapeutics of COVID-19: A comprehensive review. J Med Virol. 2021;93:275–99. - PMC - PubMed

LinkOut - more resources